Table 3.
Comparison of clinical and pathological factors among patients with baseline suPAR levels below/above the ideal prognostic cut-off value.
| baseline suPAR level <4.86 ng/ml | baseline suPAR level >4.86 ng/ml | |
|---|---|---|
| Total number of patients [n]: | 35 | 52 |
| Gender [n, (%)]: | ||
| female/male | 13/22 (37.1/62.9) | 15/37 (28.8/71.2) |
| Age [years, median and range] | 67 (45–87) | 67 (38–87) |
| BMI [kg/m2, median and range] | 25.7 (17–41.4) | 22.4 (15.9–42.3) |
| Staging [n, (%)]: | ||
| UICC III/UICC IV | 3/32 (8.6/91.4) | 2/47 (4.1/95.9) |
| Previous systemic therapy before ICI? [n, (%)]: | ||
| Yes/No | 15/20 (42.9/57.1) | 11/41 (21.2/78.8) |
| ECOG PS [n, (%)]: | ||
| ECOG 0 | 3 (8.8) | 3 (6) |
| ECOG 1 | 19 (55.9) | 26 (52) |
| ECOG 2 | 12 (35.3) | 21 (42) |
| Smoking status [n, (%)]: | ||
| Never | 3 (8.6) | 4 (7.7) |
| Previous | 13 (37.1) | 22 (42.3) |
| Present | 6 (17.1) | 11 (21.2) |
| unknown | 13 (37.2) | 15 (28.8) |
BMI, body mass index; ECOG PS, “Eastern Cooperative Oncology Group” performance status; ICI, immune checkpoint inhibitor; suPAR, soluble urokinase plasminogen activator receptor; UICC, Union for International Cancer Control.